In 2024, AI's role in precision medicine expanded, focusing on cancer diagnosis, therapy personalization, and outcome prediction. Companies like Zephyr, VieCure, and Tempus raised significant funds for AI-driven healthcare solutions. Biopharma giants invested in AI for clinical trials and drug development. AI tools for cancer screening, such as Qure.ai's qXR and Imidex's VisiRad XR, gained FDA clearance. AI-driven biomarkers and digital pathology advanced, with tools like Novigenix's LITOSeek and Ataraxis AI's digital pathology test showing promise. The future points towards larger, multimodal AI models for improved patient care.